Sjogren's Syndrome Clinical Trials

NCT ID: NCT04988087 Terminated - Sjogren Syndrome Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

This study is a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).

NCT ID: NCT04839315 Terminated - Osteoarthritis Clinical Trials

COVID-19 Vaccination in Rheumatic Disease Patients

Start date: February 15, 2021
Phase: Early Phase 1
Study type: Interventional

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

NCT ID: NCT04700280 Terminated - Clinical trials for Primary Sjögren Syndrome

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

GLIDER

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.

NCT ID: NCT04684654 Terminated - Clinical trials for Healthy Participants

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Start date: February 16, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.

NCT ID: NCT04143841 Terminated - Dry Eye Syndromes Clinical Trials

Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease

OMNS

Start date: October 30, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of Viveye OMNS non-invasive treatment for management of the signs and symptoms of severe dry eye disease.

NCT ID: NCT04035668 Terminated - Sjögren Syndrome Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

LOUiSSe

Start date: July 12, 2019
Phase: Phase 2
Study type: Interventional

This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome. LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor.

NCT ID: NCT03937856 Terminated - Clinical trials for Systemic Lupus Erythematosus

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

Start date: May 7, 2019
Phase: N/A
Study type: Interventional

This study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease.

NCT ID: NCT02843659 Terminated - Sjögren's Syndrome Clinical Trials

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Start date: October 18, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.

NCT ID: NCT02610543 Terminated - Clinical trials for Primary Sjögren's Syndrome

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS). The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.

NCT ID: NCT02503176 Terminated - Clinical trials for Dry Eye With Sjögren's Syndrome

An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.

Sjogren's Syndrome clinical trials